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The gastrointestinal peptide hormone ghrelin is the endogenous ligand of the growth hor-
mone secretagogue receptor (a.k.a. ghrelin receptor, GHR). Currently, ghrelin is the only
circulating peripheral hormone with the ability to promote a positive energy balance by
stimulating food intake while decreasing energy expenditure and body fat utilization, as
defined in rodents. Based on these and additional, beneficial effects on metabolism, the
endogenous ghrelin system is considered an attractive target to treat diverse pathologi-
cal conditions including those associated with eating/wasting disorders and cachexia. As
the pharmacological potential of ghrelin is hampered by its relatively short half-life, ghre-
lin analogs with enhanced pharmacokinetics offer the potential to sustainably improve
metabolism. One of these ghrelin analogs is the pentapeptide RM-131, which promotes
food intake and adiposity with higher potency as compared to native ghrelin in rodents.
Whereas, the effect of RM-131 on energy metabolism is solidly confirmed in rodents, it
remains elusive whether RM-131 exerts its effect solely via the ghrelin receptor. Accord-
ingly, we assessed the receptor specificity of RM-131 to promote food intake and adiposity
in mice lacking the GHR. Our data show that in wildtype mice RM-131 potently promotes
weight gain and adiposity through stimulation of food intake. However, RM-131 fails to
affect food intake and body weight in mice lacking the GHR, underlining that the anabolic
effects of RM-131 are mediated via the ghrelin receptor in mice.
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INTRODUCTION
The gastrointestinal peptide hormone ghrelin is a key periph-
eral hormone implicated in a myriad of metabolic functions.
Presently, ghrelin is the only known peripheral hormone that
promotes body weight gain and adiposity through stimulation of
food intake while decreasing energy expenditure and lipid utiliza-
tion (1). In addition to its ability to regulate energy metabolism
via hypothalamic (2–4) and non-hypothalamic (5, 6) neurocir-
cuits, ghrelin exerts a series of effects on metabolism. Accord-
ingly, ghrelin acutely promotes the release of growth hormone
from the anterior pituitary (7) regulates glucose metabolism upon
chronic systemic treatment (8, 9), stimulates lipogenesis in white
adipose tissue (10), acutely enhances gastric acid secretion and
gut motility (11–13), modulates reward seeking behavior and
taste sensation (14–17), lowers non-shivering thermogenesis of
brown adipose tissue (18, 19), has cardioprotective effects (20–
22), and protects against muscle atrophy (23, 24). In line with a
growing number of preclinical and clinical studies, the numer-
ous beneficial effects of ghrelin make the endogenous ghrelin
system an attractive therapeutic target for a series of patho-
logical conditions. As such, ghrelin and its analogs might offer
potential to treat cachexia (25, 26), sarcopenia (27), myopenia
(28), gastroparesis (29), or anorexia nervosa (26) whereas inhibi-
tion of ghrelin signaling might offer potential to treat obesity and
diabetes (30).
Ghrelin promotes its biologic action via activation of the
growth hormone secretagogue receptor (GHSR, also referred to
as the ghrelin receptor; GHR), a seven transmembrane G protein-
coupled receptor with wide distribution in human tissues (31,
32). A spliced variant of the GHR, the GHSR1a seems to be the
only endogenous active ghrelin receptor, since neither central (33)
nor peripheral (34) ghrelin administration affects systems metab-
olism in mice lacking the GHR gene. To bind and activate its
receptor, ghrelin requires acylation of its serine 3 residue with an
n-octanoic or n-decanoic acid (7), a post-translational modifica-
tion achieved by the ghrelin-O-acyltransferase (GOAT) (35, 36).
Whereas, the pharmacological potential of GHR pathway modu-
lation has been emphasized in a series of preclinical and clinical
studies [as reviewed in Ref. (26, 37)], the efficacy of acyl-ghrelin
to improve systems metabolism is hampered by its relatively short
half-life, which, depending on the species, varies between 30 min
in rats and 240 min in humans (38).
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Whereas, the pharmacological potential of acyl-ghrelin is lim-
ited by its rapid degradation and the fragility of its serine 3
acylation, ghrelin mimetics offer potential to more sustainably
improve systems metabolism. The pentapeptide RM-131 (BIM-
28131) confers increased bioavailability and improved pharmaco-
kinetic properties as compared to the native peptide. RM-131 has
a high in vitro affinity to bind and activate GHSR1a (39) and its
chronic systemic administration in rodents increases body weight
gain and adiposity through stimulation of food intake (40–42).
The orexigenic effects of RM-131 are mediated by stimulation
of meal size, meal numbers, and meal duration (41, 43) and are
paralleled by increased c-fos immunoreactivity in arcuate nucleus
AgRP/NPY neurons (43). Similar to ghrelin, RM-131 stimulates
growth hormone release from the anterior pituitary (43), increases
GI motility and gastric emptying (39, 44, 45), and reduces inflam-
mation and tissue wasting in animal models of cachexia (40, 46, 47)
and of inflammatory bowel disease (39, 40). Compared to native
human ghrelin, RM-131 is about 10- to 100-fold more potent, and
it is 600- to 1,800-fold more potent compared to ghrelin mimetics
tested thus far in clinical trials (39). The first clinical studies using
RM-131, which is in phase 2 clinical trials for the treatment of
diabetic gastroparesis and intestinal dysmotility disorders, report
that a single subcutaneous administration of RM-131 accelerates
gastric emptying in type 2 diabetic patients with gastroparesis
(45). These and a series of preclinical data support the therapeutic
potential of RM-131 to improve systems metabolism. However,
uncertainty remains about whether RM-131 exerts its in vivo
effects solely via GHSR1a signaling. In this study, we assessed
whether the anabolic action of RM-131 is exclusively attribut-
able to GHSR1a signaling in mice. In line with previous reports,
we show that RM-131 potently enhances both acute and chronic
food intake and adiposity in wildtype (wt) mice. We show that
RM-131 has no effect on food intake, body weight, and adiposity
in mice lacking the GHR. In summary, our data support the thera-
peutic potential of RM-131 to accelerate caloric intake and weight
gain and indicate that the in vivo anabolic effects of RM-131 are
exclusively mediated via the ghrelin receptor in mice.
MATERIALS AND METHODS
ANIMALS AND ACUTE FOOD INTAKE ASSESSMENTS
All animal experiments and procedures were approved by the Ani-
mal Use and Care Committee of Bavaria, Germany. The mice were
on a pure C57BL/6J background and were bred in house under
standard laboratory conditions (constant humidity, 12/12 h light
dark cycle, 22± 1°C). For the measurement of 24 h acute food
intake, non-fasted mice were single housed whereas for the 7-day
chronic study the mice were double-housed. All test compounds
were solved in H2O containing 5% mannitol. The effect of RM-131
on acute food intake was assessed in 10-week-old male chow-fed
C57BL6/J wt (N = 40; 26.71± 0.14 g) and GHR knock-out (ko)
mice (N = 40; 26.75± 0.22 g). Mice were matched for body weight
and body fat mass (N = 8 each group) and treated with a single
subcutaneous injection of either rat ghrelin (500 or 5,000 nmol/kg,
PolyPeptide Laboratories, Strasbourg, France), RM-131 (250 or
500 nmol/kg) or vehicle control (H2O containing 5% mannitol).
Acute food intake was measured at time points 0.5, 1, 2, 4, 8, 12,
and 24 h post-ghrelin treatment.
CHRONIC PERIPHERAL TREATMENT OF RM-131 IN WT AND GHR KO
MICE
The chronic effect of RM-131 on body weight, body composition
(fat and lean mass), and food intake was measured in 13-week old
male chow-fed C57BL6/J wt (N = 32; 28.09± 0.2 g) and GHR ko
mice (N = 32; 28.36± 0.24 g). The mice were matched for body
weight and body fat mass (N = 8 each group) and treated for seven
consecutive days via daily subcutaneous injections of either rat
ghrelin (5,000 nmol/kg), RM-131 (50 or 500 nmol/kg), or vehicle
(H2O containing 5% mannitol). Body composition (fat and lean
tissue mass) was assessed at study day 7 using MRI technology
(EchoMRI, Houston, TX, USA) as previously described (48).
DATA ANALYSIS
Differences between treatment groups were assessed by one-way or
two-way ANOVA followed by Bonferroni post hoc test as appropri-
ate. All results are given as means± SEM. Results were considered
statistically significant when p< 0.05, with the significance level
indicated as *(p< 0.05), **(p< 0.01), and ***(p< 0.001).
RESULTS
RM-131 STIMULATES ACUTE FOOD INTAKE IN WT BUT NOT GHR KO
MICE
To assess the effects of RM-131 and ghrelin on acute food intake,
C57Bl/6J wt and GHR ko mice were treated with a single subcu-
taneous injection of either rat ghrelin (500 and 5,000 nmol/kg),
RM-131 (250 and 500 nmol/kg), or vehicle control. In wt mice,
we observed an immediate dose-dependent increase in acute food
intake following administration of both ghrelin (Figures 1A,B)
and RM-131 (Figures 1C,D). For both ghrelin and RM-131, the
greatest peak of compound-stimulated food intake was observed
2 h post-injection (Figure 1E). In line with previous reports indi-
cating that RM-131 has a greater potency to promote food intake
relative to native ghrelin (42), we observed a greater increase in
food intake in mice treated with 500 nmol/kg RM-131 (area under
curve p< 0.001, Figure 1K) as compared to an equimolar dose
of native ghrelin (area under curve p< 0.01, Figure 1K). Impor-
tantly, we observed neither for RM-131 nor for ghrelin an effect on
acute food intake in the GHR ko mice (Figures 1F–K) with a sim-
ilar 24 h time-course of food intake between the vehicle treated wt
mice and all treatment groups of the GHR ko mice (all p> 0.05).
CHRONIC SYSTEMIC ADMINISTRATION OF RM-131 PROMOTES BODY
WEIGHT GAIN AND ADIPOSITY THROUGH GHR SIGNALING
To assess the chronic effects of RM-131 on food intake and adipos-
ity, C57Bl/6J wt and GHR ko mice were treated for seven consec-
utive days with once daily subcutaneous injections of RM-131 (50
and 500 nmol/kg), rat ghrelin (5,000 nmol/kg), or vehicle control.
In wt mice, administration of rat ghrelin (5,000 nmol/kg) signifi-
cantly increased body weight and body fat mass relative to vehicle
treated controls (Figures 2A,B). Neither food intake nor lean tissue
mass was different between the ghrelin treated wt mice and vehi-
cle treated controls (Figures 2B,C). Treatment of wt mice with
RM-131 at concentrations of 50 or 500 nmol/kg both increased
body weight relative to vehicle controls (both p< 0.01). However,
body weight gain was significantly greater in mice treated with
500 nmol/kg RM-131 compared to mice treated with 50 nmol/kg
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FIGURE 1 | Acute effect of RM-131 on food intake in wt and GHR ko mice.
Acute 24 h food intake in C57Bl/6J wt and GHR ko mice treated with a single
subcutaneous injection of vehicle, ghrelin (500 or 5,000 nmol/kg) or RM-131
(250 or 500 nmol/kg) (A–K). Effects on 24 h cumulative food intake (A–D,F–I),
fold-increase in food intake relative to mice treated with vehicle (E,J), and
area under curve of the 24-h food intake (K). N =8 mice each genotype and
treatment group. Data represent means±SEM. Asterisks indicate *p<0.05;
**p<0.01; ***p<0.001.
RM-131 (p< 0.0001) and as compared to mice treated with a 10-
fold higher dose of ghrelin (5,000 nmol/kg; p< 0.05) (Figure 2A).
As in the ghrelin treated mice, mice treated with RM-131 dis-
played an increase in body weight that was a result of an increase
in body fat but not lean tissue mass (Figure 2B). Notably, food
intake was increased only in wt mice treated with 500 nmol/kg
RM-131 (p< 0.05) but not in mice treated with 50 nmol/kg RM-
131 or 5,000 nmol/kg ghrelin (Figure 2C). In line with our study
showing that RM-131 promotes food intake exclusively via the
GHR, we observed no effect of RM-131 at concentrations of 50
or 500 nmol/kg on body weight (Figure 2D), body composition
(Figure 2E), or food intake (Figure 2F) in the GHR ko mice relative
to their vehicle treated controls.
DISCUSSION
A series of preclinical and clinical data support the therapeu-
tic potential of ghrelin and its analogs to improve pathological
conditions associated with eating/wasting disorders and cachexia
(26), intestinal dysmotility disorders (49), and diabetic gastro-
paresis (39, 44, 45). However, whereas the therapeutic potential
of GHSR1a pathway modulation is generally acknowledged, the
pharmacological value of native ghrelin is limited by its rapid
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FIGURE 2 | Chronic effect of RM-131 on food intake, body weight,
and body composition in C57BL/6J wt and GHR ko mice. Body
weight, body composition (fat and lean tissue mass), and cumulative
food intake in wt (A–C) and GHR ko mice (D–F) treated with daily
subcutaneous injections of ghrelin (5,000 nmol/kg), RM-131 (50 or
500 nmol/kg), or vehicle control. N =8 each genotype and treatment
group. Data represent means±SEM. Asterisks indicate *p<0.05;
**p<0.01; ***p<0.001.
degradation and the fragility of its serine 3 acylation. Several clin-
ical studies report beneficial effects of ghrelin administration on
food intake in healthy individuals (50–52), patients with anorexia
nervosa (53), and in patients with cachexia associated with can-
cer (54), chronic obstructive pulmonary disease (COPD) (55) and
renal failure (56, 57). However, not all studies were able to repli-
cate these findings (25, 58, 59). Potential pitfalls of these studies
are the limited amount of patients analyzed and the overall short
duration of ghrelin treatment. Nevertheless, based on the rela-
tive short half-life of the native peptide, ghrelin mimetics, which
overcome these issues are predicted to more sustainably improve
metabolic and other clinical parameters. Several clinical studies
have assessed the therapeutic potential of ghrelin mimetics, such
as anamorelin (RC-1291) (52), ulimorelin (TZP-101) (60–62), and
RM-131 (44, 45) for the treatment of cachexia, gastroparesis, and
gastric/intestinal dysmobility disorders. Whereas, TZP-101 had
only limited success to improve gastroparesis in a large-scale clin-
ical study (63), the pentapeptide RM-131, exerts superior effects
on systems metabolism as compared to native ghrelin and other
ghrelin mimetics so far tested in clinical trials (39). However, it
remains elusive whether RM-131 exerts its in vivo anabolic effects
exclusively via GHR activation. Accordingly, the aim of this study
was to assess whether RM-131 promotes food intake and adipos-
ity via GHR signaling in vivo. In line with previous studies, our
data show that in wt mice, RM-131 potently enhances food intake,
body weight, and adiposity. We show that RM-131 has no effect
on food intake and body weight gain in mice lacking the GHR
(including the active/spliced variant GHSR1a), indicating that the
anabolic effects of RM-131 are exclusively mediated via the ghrelin
receptor in mice.
In summary, our data align with numerous reports indicating
that GHSR1a pathway modulation is a promising and powerful
tool to promote food intake and adiposity, underscoring the ther-
apeutic potential of manipulating the endogenous ghrelin system
to treat pathological conditions associated with excessive tissue
wasting and cachexia. Our data also support previous findings
indicating that RM-131 promotes its biological action at con-
centrations 10- to 100-fold lower than native ghrelin. However,
whereas our studies clearly show that RM-131 promotes food
intake and adiposity exclusively via the ghrelin receptor in mice,
more studies are warranted to assess whether more complex func-
tions of ghrelin, such as the regulation of reward seeking behavior,
taste sensation, and protection of muscle atrophy, are mediated via
RM-131-GHSR1a interaction. In addition, based on the superior
anabolic efficacy of RM-131 compared to native ghrelin, RM-131
holds promise for proof of concept experiments in mice to evaluate
potentially clinically beneficial effects of RM-131 in diet-induced
obesity, with relative ghrelin resistance (64).
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